Opinion|Videos|November 8, 2024
From Guidelines to Practice: Advancing Lupus Nephritis Treatment
Author(s)Amit Saxena, MD
Amit Saxena, MD, discusses how evidence-based guidelines from ACR and KDIGO have evolved to shape lupus nephritis treatment approaches, emphasizing their critical role in standardizing patient care and incorporating recent advances like new therapeutic options and refined diagnostic criteria.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- In your view, why are guidelines for lupus nephritis important to patient care?
- What role do the American College of Rheumatology (ACR) and Kidney Disease Improving Global Outcomes (KDIGO) guidelines play in shaping treatment practices for lupus nephritis?
- What are some of the most significant recent changes in lupus nephritis guidelines?
- How has the treatment approach for lupus nephritis evolved in recent years alongside these guidelines?
Advertisement
Related to this article
Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.
AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.
Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.
Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.
Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.
Karolinska Institutet reports ROR1 inhibitor KAN571C wipes out double‑resistant MCL after ibrutinib/venetoclax, spotlighting a promising target.
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
2
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
3
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
4
Twice-Yearly CD19 Therapy Targets MG Root Cause: Richard Nowak, MD, MS
5